Clinton Haley, MD
Infectious Disease · Dallas, TXNPI 1871733188
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 867 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Viiv Healthcare Company at 33.9% of the total. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 867 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$6K
- Merck$1K
- Insmed, Inc.$1K
- Gilead$1K
- AbbVie$818
- Paratek Pharmaceuticals, Inc.$806
- plus $6K from 23 others
Across 16 payments — averaging $1993.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$32K
What the payments were for
- Speaking & faculty fees$570%
- Food & beverage$16,78198%
- Education$2912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 258 | $5,812 |
| Merck | 72 | $1,307 |
| Insmed, Inc. | 53 | $1,213 |
| Gilead | 58 | $1,158 |
| AbbVie(2 entities) | 38 | $818 |
| Paratek Pharmaceuticals, Inc. | 55 | $806 |
| EMD Serono, Inc. | 43 | $682 |
| Johnson & Johnson | 42 | $653 |
| Shionogi Inc | 35 | $589 |
| Astellas Pharma US Inc | 28 | $569 |
| Theratechnologies Inc. | 29 | $511 |
| Ferring Pharmaceuticals Inc. | 15 | $418 |
| Aimmune Therapeutics, Inc. | 18 | $348 |
| Napo Pharmaceuticals Inc | 17 | $334 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $284 |
| Cumberland Pharmaceuticals, Inc. | 16 | $261 |
| Mayne Pharma Commercial LLC | 11 | $205 |
| Grifols USA, LLC | 9 | $201 |
| Melinta Therapeutics, LLC | 13 | $189 |
| La Jolla Pharmaceutical Company | 9 | $170 |
| Amgen | 6 | $109 |
| Tetraphase Pharmaceuticals, Inc. | 9 | $106 |
| Pfizer | 5 | $98 |
| Hospira, Inc. | 4 | $69 |
| Invivyd Inc | 3 | $59 |
| Nabriva Therapeutics, PLC | 4 | $53 |
| Octapharma USA, Inc. | 2 | $52 |
| Amarin Pharma, Inc. | 2 | $46 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,130 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 110 | $445,417 |
| DovatoDolutegravir Sodium/Lamivudine | 80 | $235,569 |
| PrezcobixDarunavir/Cobicistat | 51 | $123,102 |
| CabenuvaCabotegravir/Rilpivirine | 17 | $116,631 |
| Egrifta SvTesamorelin Acetate | 15 | $109,412 |
| Daptomycin | 207 | $101,698 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 22 | $101,089 |
| TivicayDolutegravir Sodium | 33 | $70,839 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 17 | $66,055 |
| ErtapenemErtapenem Sodium | 155 | $59,741 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 15 | $56,232 |
| DescovyEmtricitabine/Tenofov Alafenam | 25 | $52,971 |
| ZerbaxaCeftolozane/Tazobactam | 23 | $50,855 |
| JulucaDolutegravir/Rilpivirine | 14 | $49,428 |
| Meropenem | 61 | $20,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $1,158 | $564,443152 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay, Triumeq, Juluca | $5,812 | $528,700159 claims |
| Johnson & JohnsonPrezcobix | $653 | $123,10251 claims |
| Theratechnologies Inc.Egrifta Sv | $511 | $109,41215 claims |
| MerckZerbaxa | $1,307 | $50,85523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Dallas
- Elizabeth RaceDallas$1.5M
- Uriel SandkovskyDallas$320K
- Roger BedimoDallas$269K
- Edward DominguezDallas$121K
- Robert HardyDallas$116K
- Mezgebe BerheDallas$66K
- Ank NijhawanDallas$39K
- Philip KeiserDallas$38K
- Helen KingDallas$37K
- Jason GillmanDallas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.